Clinical trials: Open Access
Bowel Preparation
1L-PEG-Asc Solution for Bowel Preparation in an "Open Access" Colonoscopy Booking System: Evaluation of Adverse Events
Several factors are considered as the key indicators of quality colonoscopy, including endoscopist experience, withdrawal time, and quality of bowel preparation (BP).
- Trial name
- NCT04970173
- Testing
- use of a very low-volume 1L-PEG plus ascorbate (plenvu) or low-volume 2L-PEG plus ascorbate (moviprep) for bowel preparation in open access colonoscopy
- Where
- Italy
- Volunteers
- 5,981 people
- Sponsor
- Azienda USL Modena
HIV Infections
Fuzeon (Enfuvirtide) Early Access Program for Patients With HIV-1 Infection
This study will determine the safety and tolerability of Fuzeon (enfuvirtide) used together with other treatments for HIV infection in patients with advanced HIV disease. Fuzeon is an antiretroviral drug.
- Trial name
- NCT00050856
- Testing
- Enfuvirtide T/20/Ro 29,9800, HIV-1 Infusion Inhibitor
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
CD55-Deficient Protein-Losing Enteropathy
Compassionate Use of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy
The program is to provide access to an experimental drug called pozelimab and to document the long-term safety of pozelimab in patients with Protein-Losing Enteropathy (PLE).
- Trial name
- CHAPLE Disease (NCT06003881)
- Testing
- Pozelimab
- Sponsor
- Regeneron Pharmaceuticals
Malignant Melanoma
A Study of RO5185426 in Patients With Metastatic Melanoma
This is an open-label, non-comparative, multicenter, expanded access study of RO5185426 in patients who have received prior systemic therapy for metastatic melanoma and who have no other satisfactory treatment options.
- Trial name
- NCT01248936
- Testing
- RO5185426
- Where
- 28 sites in United States
- Volunteers
- 374 people
- Sponsor
- Hoffmann-La Roche
TNBC, TNBC - Triple-Negative Breast Cancer
An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC)
This Expanded Access Program provides investigational access to leronlimab (PRO 140) for patients with advanced or metastatic triple-negative breast cancer (TNBC) who lack satisfactory treatment options and are unable to…
- Conditions
- TNBC, TNBC - Triple-Negative Breast Cancer, TNBC, Triple Negative Breast Cancer
- Trial name
- NCT07536815
- Testing
- leronlimab (PRO 140)
- Where
- United States
- Sponsor
- CytoDyn, Inc.
Neuroblastoma, Pheochromocytoma
Expanded Access Protocol Using 131I-MIBG
Protocol JDI2007-01 is an Expanded Access Protocol with therapeutic 131I-MIBG for patients with neuroblastoma or pheochromocytoma / paraganglioma, who otherwise do not qualify for available treatments, or where approved treatment…
- Conditions
- Neuroblastoma, Pheochromocytoma, Paraganglioma
- Trial name
- NCT01590680
- Testing
- I-131 MIBG
- Where
- 19 sites in United States
- Sponsor
- Jubilant DraxImage Inc.
Hypereosinophilic Syndrome
This Record Contains Information About the Mepolizumab Compassionate Use (CU) Product Activities: 104317: CU and Long-Term Access Study of Mepolizumab in HES. 201956:A Long-term Access Programme for Subjects With Severe Asthma 112562: Expanded Access for Patients With Hypereosinophilic
104317: The market authorisation application for mepolizumab for the indication of hypereosinophilic syndrome (HES) was filed in 2008, but later the file was withdrawn due to outstanding questions from regulator's raised from the…
- Trial name
- NCT00244686
- Testing
- Mepolizumab
- Sponsor
- GlaxoSmithKline
Chronic Kidney Disease
A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)
This research study is designed to assess the safety and effectiveness of an experimental drug called vonapanitase (PRT-201) in patients both receiving or expecting to receive hemodialysis who have chronic kidney disease and who…
- Trial name
- NCT02414841
- Testing
- Vonapanitase
- Where
- 41 sites in United States, Canada
- Volunteers
- 696 people
- Sponsor
- Proteon Therapeutics
Solid Tumor, Peritoneal Metastasis
A Phase II Clinical Study to Evaluate the Efficacy and Safety of Technetium [99mtc]-H7ND Injection in the Diagnosis of Peritoneal Metastasis of Gastrointestinal Malignant Tumor.
The main purpose of this study is to evaluate the effectiveness of technetium [99mTc]-H7ND injection in the diagnosis of peritoneal metastasis of gastrointestinal malignant tumor.
- Trial name
- NCT07107633
- Testing
- Technetium [99mTc]-H7ND injection
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Jiaxing Pharmadax Genesis Pharmaceutical Technology Co.,Ltd.
Frontotemporal Dementia
An Open-Label, Expanded Access Protocol of LAM-002A in C9ORF72-Associated Frontotemporal Dementia (FTD)
This is an open-label, single subject, expanded access protocol (EAP) of the LAM-002A investigational product administered orally at 125 mg BID for 52 weeks.
- Trial name
- NCT05483322
- Testing
- LAM-002A
- Sponsor
- IRulya Therapeutics Inc.
Accuracy of Digital Dental Model
Accuracy of Digital Models Using Open-access Software Programs
Background: Despite the clear drive toward digital model transformation, there are limitations to some paid software necessary for digital model production.
- Trial name
- NCT06035432
- Testing
- Bluesky software, 3D slicer software, OnDemand software
- Where
- Egypt
- Volunteers
- 18 people
- Sponsor
- Hams Hamed Abdelrahman
Type 2 Diabetes
The Metabolite Identification and Material Balance Study of SP2086
The purpose of the study is to investigate the Metabolite identification and material balance of SP2086 in healthy adult volunteers.
- Trial name
- NCT02815748
- Testing
- SP2086
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Human Immunodeficiency Virus (HIV)
A Treatment Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India
The new protocol will allow the patients enrolled on A4001050 to have continuous access of Maraviroc and the treatment will not be interrupted until the drug is commercially available in India.
- Trial name
- NCT00992654
- Testing
- Open Label Treatment Access: Maraviroc
- Sponsor
- ViiV Healthcare
Transradial Access
Transradial Access for Ruptured Intracranial Aneurysms Embolization
The goal of this clinical trail is to compare the difference between transradial access (TRA) and transfemoral access(TFA) for ruptured intracranial aneurysms embolization.
- Trial name
- TRA-RIA (NCT05851274)
- Testing
- transradial access, Transfemoral access
- Where
- China
- Volunteers
- 242 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Breast Cancer
An Open-Label, Expanded Access Protocol of Iniparib Breast Cancer
The following trial is designed to offer pre-approval drug access to iniparib in combination with gemcitabine and carboplatin in order to provide potential clinical benefit to patients with ER-, PR-, and HER2-negative metastatic…
- Trial name
- NCT01130259
- Testing
- iniparib
- Sponsor
- Sanofi
Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia
The purpose of the current study is to evaluate additional safety data of bendamustine in up to 100 patients with Indolent Non-Hodgkin's Lymphoma (iNHL) relapsing from a rituximab regimen or Chronic Lymphocytic Leukemia (CLL).
- Trial name
- BENDACT (NCT01500083)
- Testing
- Bendamustine at a dose of 100 mg/m2, Bendamustine at a dose of 120 mg/m2
- Where
- 16 sites in Canada
- Volunteers
- 90 people
- Sponsor
- Lundbeck Canada Inc.
Attention Deficit Hyperactivity Disorder (ADHD)
Access to Extended Release Guanfacine HCl for Subjects Who Participated in Studies SPD503-315 or SPD503-316 in Europe
For subjects in Europe that have already participated in either Study SPD503-315 or SPD503-316. This is an extension study that will allow participants access to Extended-release Guanfacine Hydrochloride (HCl) for up to 2 years.
- Trial name
- NCT01500694
- Testing
- Extended-release Guanfacine HCl (Intuniv, SPD503)
- Where
- 60 sites in Austria, Belgium and 11 more
- Volunteers
- 215 people
- Sponsor
- Shire
Fabry Disease
Open-Label Expanded Access Treatment With Pegunigalsidase Alfa for Fabry Disease Patients
The objective of this treatment protocol is to provide guidance to Treating Physicians who seek access to pegunigalsidase alfa for Fabry patients whose clinical condition, in the opinion of the Treating Physician, requires…
- Trial name
- NCT04552691
- Testing
- Pegunigalsidase Alfa
- Where
- 11 sites in United States
- Sponsor
- Chiesi Farmaceutici S.p.A.
Hemostasis of Arterial Punctures
Clinical Use Study of SAPH Device for Patent Hemostasis After a Transradial Procedure
This is a prospective, multicenter study intended to provide supportive clinical information on the use of the SAPH device to achieve radial artery patent hemostasis after a transradial procedure.
- Trial name
- NCT06991010
- Testing
- Suction-Activated Patent Hemostasis (SAPH) Device
- Volunteers
- 50 people
- Sponsor
- Transradial Technologies, LLC
Pediatric Renal Tumor, Metastatic Osteosarcoma
Indo-cyanine Green (ICG) in Paediatric Oncology MIS
Indo-cyanine green (ICG) is a dye that has been used for a variety of adult and paediatric uses since 1956. Over the past few years, near infrared (NIRF) technology has been developed which allow is use as a fluorescence agent…
- Conditions
- Pediatric Renal Tumor, Metastatic Osteosarcoma, Metastatic Ewing Sarcoma, Pulmonary Metastasis
- Trial name
- NCT04854018
- Testing
- Indocyanine green
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Birmingham Women's and Children's NHS Foundation Trust